

![]() |
A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study |
|
Authors | ||
Published in | The American journal of gastroenterology. 2007, vol. 102, no. 7, p. 1397-405 | |
Abstract | In patients with cirrhosis, acute octreotide administration may transiently decrease the hepatic venous pressure gradient (HVPG). Information on long-term effects of octreotide is limited and controversial. We evaluated portal and systemic hemodynamics following a prolonged administration of long-acting octreotide in patients with cirrhosis. | |
Keywords | Adult — Aged — Biological Markers/blood — Biopsy — Delayed-Action Preparations — Double-Blind Method — Endothelin-1/blood — Female — Follow-Up Studies — Gastrointestinal Agents/administration & dosage/pharmacokinetics — Humans — Hypertension, Portal/drug therapy/etiology/physiopathology — Immunoenzyme Techniques — Injections, Intramuscular — Liver Cirrhosis/blood/complications/pathology — Male — Middle Aged — Octreotide/administration & dosage/pharmacokinetics — Portal Pressure/physiology — Radioimmunoassay — Retrospective Studies — Time Factors — Treatment Outcome — Urotensins/blood — Vascular Endothelial Growth Factor A/blood | |
Identifiers | PMID: 17488248 | |
Full text | ||
Structures | ||
Research groups | Hépatologie chirurgicale (327) Physiopathologie de la pancréatite aiguë (601) | |
Citation (ISO format) | SPAHR, Laurent François Joséph et al. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study. In: The American journal of gastroenterology, 2007, vol. 102, n° 7, p. 1397-405. doi: 10.1111/j.1572-0241.2007.01262.x https://archive-ouverte.unige.ch/unige:35201 |